QT-prolongation
Conditions
Keywords
QT-prolongation, Torsade de Pointes, Haloperidol, Drug interactions
Brief summary
In this epidemiological point prevalence study, medication profiles of patients with haloperidol treatment will be checked for drug interactions with risk of QT-prolongation. Additional clinical risk factors for developing QT-prolongation and safety measurements will be documented.
Detailed description
Study design: epidemiological point prevalence study Target population: Patients with haloperidol treatment The following aspects will be investigated: * The medication profiles will be checked for drug interactions with risk of QT-prolongation. * Clinical risk factors for developing QT-prolongation (gender, age, (history of) cardiovascular disease, comorbidity,...) and lab results will be collected. * Safety measurements (e.g. ECG) will be documented.
Interventions
DRUGHaloperidol
Sponsors
Agentschap voor Innovatie door Wetenschap en Technologie
KU Leuven
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* treatment with haloperidol (started in the hospital)
Exclusion criteria
* age \< 18 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| QTc-interval (corrected for heart rate) | maximum one year before inclusion / one week after inclusion |
Secondary
| Measure | Time frame |
|---|---|
| number of drug interactions (with risk of QT-prolongation) | one week before/after inclusion |
Other
| Measure | Time frame |
|---|---|
| number of patients with an ECG before or after the start of haloperidol | maximum one year before inclusion / one week after inclusion |
Countries
Belgium
Outcome results
None listed